Business
QIAGEN Appoints Mark Stevenson to Supervisory Board
VENLO, Netherlands, January 26, 2026--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026.
About this update from Qiagen N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":242,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/71ef39d7082c8dc78df8c6c0c9adec08"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vi6AGcEmq8aUsh2ZwYrviw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/71ef39d7082c8dc78df8c6c0c9adec08","width":242,"height":204}},"lazy":false},{"type":"text","content":"VENLO, Netherlands, January 26, 2026--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026.","length":311,"tagName":"p"},{"type":"text","content":"In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board.","length":302,"tagName":"p"},{"type":"text","content":""We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Mark brings deep operational leadership and global life sciences experience at scale. His background will further strengthen the Supervisory Board’s ability to provide effective oversight and support disciplined capital allocation."","length":385,"tagName":"p"},{"type":"text","content":""I would also like to express our sincere appreciation to Ross Levine for his outstanding service on the Supervisory Board over the last decade," Mr. Rusckowski said. "Ross is an esteemed physician-scientist whose scientific leadership and clinical perspectives have made a lasting contribution to QIAGEN. We wish him every success in his new leadership role and are grateful that he will continue to lead our Scientific Advisory Board, where his guidance remains critical to our innovation agenda."","length":519,"tagName":"p"},{"type":"text","content":"Mark Stevenson has more than 30 years of experience in life science technology companies, with a strong focus on operationa...